Monocyte chemoattractant protein 1 is correlated with glycemic control and peripheral arterial disease in type 2 diabetic patients with metabolic syndrome

Angiology

Volumn 64, Issue 3, 2013, Pages 223-229

  Papatheodorou, K ^a   Papanas, N ^a   Papazoglou, D ^a   Gioka, T ^b   Antonoglou, C ^a   Glaros, D ^a   Maltezos, E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

chemokines; diabetes mellitus; metabolic syndrome; peripheral arterial disease

Indexed keywords

HEMOGLOBIN A1C; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BLOOD LEVEL;

AGED; ANKLE BRACHIAL INDEX; BLOOD GLUCOSE; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS;

EID: 84876011468     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712440143     Document Type: Article

References (54)

1. Reaven GM.. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988 ; 37 (12). 1595-1607
2. Ford ES, Giles WHO, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004 ; 27 (10). 2444-2449
3. Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP. The prevalence of the metabolic syndrome using the National Cholesterol Education Program and International Diabetes Federation definitions. Curr Med Res Opin. 2005 ; 21 (8). 1157-1159
4. Liese AD, Mayer-Davis EJ, Haffner SM. Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev. 1998 ; 20 (2). 157-172
5. Meigs JB, D'Agostino RB, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes. 1997 ; 46 (10). 1594-1600
6. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001 ; 86 (2). 713-718
7. Pyoralä M, Miettinen H, Halonen P, Laakso M, Pyoralä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol. 2000 ; 20 (2). 538-544
8. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000 ; 102 (1). 42-47
9. Ingelsson E, Hulthe J, Lind L. Inflammatory markers in relation to insulin resistance and the metabolic syndrome. Eur J Clin Invest. 2008 ; 38 (7). 502-509
10. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia. 1998 ; 41 (10). 1241-1248
11. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med. 2000 ; 343 (16). 1179-1182
12. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. Eur Heart J. 2002 ; 23 (11). 831-834
13. Fernandez-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia. 1999 ; 42 (11). 1367-1374
14. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999 ; 340 (2). 115-126
15. Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis. 2002 ; 160 (1). 91-102
16. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006 ; 354 (6). 610-621
17. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A. 1994 ; 91 (9). 3652-3656
18. Xu LL, Warren MK, Rose WL, Gong W, Wang JM. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J Leukoc Biol. 1996 ; 60 (3). 365-371
19. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology. 2006 ; 147 (5). 2458-2467
20. Kouyama K, Miyake K, Zenibayashi M, et al. Association of serum MCP-1 concentration and MCP-1 polymorphism with insulin resistance in Japanese individuals with obese type 2 diabetes. Kobe J Med Sci. 2008 ; 53 (6). 345-354
21. Nelken NA, Coughlin SR, Gordon D, et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991 ; 88 (4). 1121-1127
22. Yu X, Dluz S, Graves DT, et al. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA. 1992 ; 89 (15). 6953-6957
23. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet. 2005 ; 366 (9491). 1059-1062
24. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 ; 120 (16). 1640-1645
25. Chimonas T, Athyros VG, Ganotakis E, et al. Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome. Angiology. 2010 ; 61 (1). 49-57
26. Al-Qaisi M, Nott DM, King DH, Kaddoura S. Ankle brachial pressure index (ABPI): an update for practitioners. Vasc Health Risk Manag. 2009 ; 5 (1). 833-841
27. Papanas N, Symeonidis G, Mavridis G, et al. Ankle-brachial index: a surrogate marker of microvascular complications in type 2 diabetes mellitus?. Int Angiol. 2007 ; 26 (3). 253-257
28. McDermott MM, Criqui MH, Liu K, et al. Lower ankle/brachial index, as calculated by averaging the dorsalis pedis and posterior tibial arterial pressures, and association with leg functioning in peripheral arterial disease. J Vasc Surg. 2000 ; 32 (6). 1164-1171
29. Papanas N, Kakagia D, Papatheodorou K, et al. Lanarkshire Oximetry Index as a diagnostic tool for peripheral arterial disease in type 2 diabetes: a pilot study. Angiology. 2010 ; 61 (4). 388-391
30. Piemonti L, Calori G, Mercalli A, et al. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care. 2003 ; 26 (10). 2883-2889
31. Piemonti L, Calori G, Lattuada G, et al. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care. 2009 ; 32 (11). 2105-2110
32. Mine S, Okada Y, Tanikawa T, Kawahara C, Tabata T, Tanaka Y. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem Biophys Res Commun. 2006 ; 344 (3). 780-785
33. Wasilewska A, Tenderenda E, Taranta-Janusz K, Tobolczyk J, Stypułkowska J. Markers of systemic inflammation in children with hyperuricemia [published online ahead of print December 24 2011]. Acta Paediatr. 2011 ;:
34. Li H, Deng X, Li Z, Luo C, Liu J, Wang Y. Variation of serum monocyte chemoattractant protein-1 in patients with diabetes and metabolic syndrome. J Huazhong Univ Sci Technolog Med Sci. 2011 ; 31 (3). 312-316
35. Herder C, Müller-Scholze S, Rating P, et al. Systemic monocyte chemoattractant protein-1 concentrations are independent of type 2 diabetes or parameters of obesity: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Eur J Endocrinol. 2006 ; 154 (2). 311-317
36. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003 ; 42 (5). 905-910
37. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004 ; 110 (24). 3687-3692
38. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004 ; 89 (6). 2728-2735
39. Trøseid M, Lappegård KT, Claudi T, et al. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. Eur Heart J. 2004 ; 25 (4). 349-355
40. Tabara Y, Kohara K, Yamamoto Y, et al. Polymorphism of the monocyte chemoattractant protein (MCP-1) gene is associated with the plasma level of MCP-1 but not with carotid intima-media thickness. Hypertens Res. 2003 ; 26 (9). 677-683
41. Wu JD, Xu XH, Zhu J, et al. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011 ; 13 (2). 143-148
42. Kiyici S, Erturk E, Budak F, et al. Serum monocyte chemoattractant protein-1 and monocyte adhesion molecules in type 1 diabetic patients with nephropathy. Arch Med Res. 2006 ; 37 (8). 998-1003
43. Fortes PC, Mendes JG, Stinghen A, Riella MC, Pecoits-Filho R. Metabolic syndrome is associated with increased plasma levels of monocyte chemoattractant protein in dialysis patients. Perit Dial Int. 2007 ; 27 (suppl 3). S12
44. Satiroglu O, Uydu HA, Demir A, Bostan M, Atak M, Bozkurt E. Association between plasma monocyte chemoattractant protein-1 levels and the extent of atherosclerotic peripheral artery disease. Tohoku J Exp Med. 2011 ; 224 (4). 301-306
45. Petrkova J, Szotkowska J, Hermanova Z, Lukl J, Petrek M. Monocyte chemoattractant protein-1 in patients with peripheral arterial disease. Mediators Inflamm. 2004 ; 13 (1). 39-43
46. Wakabayashi I, Masuda H. Relationships between vascular indexes and atherosclerotic risk factors in patients with type 2 diabetes mellitus. Angiology. 2008 ; 59 (5). 567-573
47. Bianchi C, Penno G, Pancani F, et al. Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes. Diabetes Res Clin Pract. 2007 ; 78 (2). 246-253
48. Deo R, Khera A, McGuire DK, et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. Am Coll Cardiol. 2004 ; 44 (9). 1812-1818
49. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin. 2004 ; 20 (6). 951-954
50. Milionis HJ, Kalantzi KJ, Goudevenos JA, Seferiadis K, Mikhailidis DP, Elisaf MS. Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subjects. J Intern Med. 2005 ; 258 (5). 435-441
51. Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology. 2007 ; 58 (4). 450-457
52. Daskalopoulou SS, Athyros VG, Hamilton G, Mikhailidis DP. Lipid-lowering therapy in patients with peripheral arterial disease. J Cardiovasc Pharmacol Ther. 2005 ; 10 (2). 145-147
53. Alnaeb ME, Alobaid N, Seifalian AM, Mikhailidis DP, Hamilton G. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg. 2006 ; 20 (5). 696-705
54. Paraskevas KI, Athyros VG, Briana DD, Kakafika AI, Karagiannis A, Mikhailidis DP. Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets. 2007 ; 8 (8). 942-951